{"Q": 1, "answer": "no", "rationale": "No intensifier or comparative directly modifies a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_5796", "batch_size": 200, "batch_pos": 87, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment uses neutral language and describes capability, lacking high-potency language for the threat's impact.", "method": "llm_batch", "batch_id": "batch_2_17672", "batch_size": 200, "batch_pos": 63, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "'plans to launch' and 'could respond' are about future actions/potential.", "method": "llm_batch", "batch_id": "batch_3_17072", "batch_size": 200, "batch_pos": 186, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_18988", "batch_size": 200, "batch_pos": 162, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "Reports plans and capability but lacks the explicit link to public safety required for Q5.", "method": "llm_batch", "batch_id": "batch_5_16504", "batch_size": 200, "batch_pos": 159, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "The segment discusses plans for a small human trial and quick response, which is preparedness/capability language, not minimiser + scale contrast.", "method": "llm_batch", "batch_id": "batch_6_17072", "batch_size": 200, "batch_pos": 126, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment states the company plans to launch a trial and could respond quickly, which are factual statements, not a bare negation or explicit calming cue.", "method": "llm_batch", "batch_id": "batch_7_2772", "batch_size": 200, "batch_pos": 105, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes future action ('plans to launch a small human trial') and capability ('could respond very quickly') without explicit reassurance.", "method": "llm_batch", "batch_id": "batch_8_17088", "batch_size": 200, "batch_pos": 147, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
